Business
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the
About this update from Biocardia, Inc.
[{"type":"text","content":"SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: JP7282649B2 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on September 30, 2034. This patent describes interventional biotherapeutic delivery catheters to deliver biologics to specific target sites from within the heart chamber. The allowed claims cover BioCardia’s helical needle tipped catheter technology platform in existing products and in future products in active development with enhanced features. “Our Helix™ minimally invasive biotherapeutic delivery platform enables the successful development of cell and gene-based therapies for the heart,” said Dr. Peter Altman, BioCardia CEO. “The Helix platform underlies BioCardia’s cell therapy clinical programs and is actively enabling important therapeutic strategies for select partners. This recent patent issuance provides additional protection to our technology and product offerings in Japan. Developers of cardiac cell-based therapies, including BioCardia, are seeking first approvals to begin marketing for the treatment of heart failure in Japan. A cardiac cell therapy has already been approved in Japan, but it requires surgical open chest delivery, whereas the Helix catheter system delivers the cell therapies it enables in a minimally invasive fashion.” The Helix transendocardial biotherapeutic delivery system has a small helical needle which engages the heart tissue and is stable within the dynamic beating heart. The platform is believed to be the safest, easiest, and most efficient way to locally deliver biotherapeutics to the heart. It has demonstrated increased effective dosing by three-fold over surgical access intramyocardial biotherapeutic delivery1 and has demonstrated enhanced procedural safety in its clinical experience2. BioCardia’s cardiac biotherapeutics under development include: BCDA-01, the pivotal CardiAMP® autologous cell therapy in ischemic heart failure with next DSMB scheduled for July 12, 2023, BCDA-02, the pivotal CardiAMP® autologous cell therapy in chronic myocardial ischemia expected to complete its roll in cohort this year, and BCDA-03, the...